MIR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-07-29

• •Our revenues were $524.4 million for the six months ended June 30, 2026 and $424.9 million for the six months ended June 30, 2025, of which 70.9% and 64.7% were generated in the Nuclear & Safety segment for the six months ended June 30, 2026 and 2025, respectively, and 29.1% and 35.3% were generate…

• •Backlog (representing committed but undelivered contracts and purchase orders) was $1,138.6 million and $1,104.3 million as of June 30, 2026, and December 31, 2025, respectively.

• We manage and report our business in two business segments: Nuclear & Safety and Medical.

• Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants ("NPPs"), we sell products and services for u…

• Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance (RT QA), which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment …

Text removed vs the prior filing · source: 10-Q · 2026-04-29

• •Remaining performance obligations (representing committed but undelivered contracts and purchase orders) was $1,120.6 million and $1,104.3 million as of March 31, 2026, and December 31, 2025, respectively.

• The following tables present a reconciliation of GAAP income from operations to non-GAAP Adjusted EBITDA by segment for the three months ended March 31, 2026, and the three months ended March 31, 2025.

• We manage and report our business in two business segments: Nuclear & Safety and Medical.

• Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants ("NPPs"), we sell products and services for u…

• Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance (RT QA), which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment …

Text added vs the prior filing · source: 10-Q · 2026-07-29

• The use of Artificial Intelligence (AI) and machine learning technologies in our business and operations may result in legal liability, regulatory action, increased compliance obligations, competitive or reputational harm, ethical or other concerns and adversely affect our business, financial condit…

• If competitors or other third parties adopt artificial intelligence more quickly or effectively than us, our competitive position, reputation and operations could be adversely affected. Further, there can be no assurance that our use of artificial intelligence will increase our efficiency or profita…

• Laws and regulations governing artificial intelligence technologies are rapidly evolving and complex, including in the areas of intellectual property, cybersecurity, privacy and data protection, employment, consumer protection, product liability, securities, defamation and other areas. Existing and …

• Although we have implemented and continue to enhance policies, procedures and governance controls intended to help address certain risks presented by these technologies, our employees may not fully abide by those controls and these measures may not fully address or prevent legal, regulatory, operati…